| Source | Code | Name | Case count | Share of cases (%) |
|---|---|---|---|---|
| REIMB | REIMB_KELA(202)_ICD10(M058) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Other seropositive rheumatoid arthritis | 2448 | |
| REIMB | REIMB_KELA(202)_ICD10(M05) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Seropositive rheumatoid arthritis | 2192 | |
| REIMB | REIMB_KELA(313)_ICD10(M058) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Other seropositive rheumatoid arthritis | 1455 | |
| REIMB | REIMB_KELA(281)_ICD10(M058) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Other seropositive rheumatoid arthritis | 1348 | |
| REIMB | REIMB_KELA(313)_ICD10(M05) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Seropositive rheumatoid arthritis | 1036 | |
| REIMB | REIMB_KELA(281)_ICD10(M05) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Seropositive rheumatoid arthritis | 881 | |
| REIMB | REIMB_KELA(202)_ICD10(M059) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Seropositive rheumatoid arthritis, unspecified | 231 | |
| REIMB | REIMB_KELA(3006)_ICD10(M058) | Baricitinib, Other seropositive rheumatoid arthritis | 138 | |
| REIMB | REIMB_KELA(291)_ICD10(M058) | Tofacitinib, Other seropositive rheumatoid arthritis | 129 | |
| REIMB | REIMB_KELA(293)_ICD10(M058) | Baricitinib, Other seropositive rheumatoid arthritis | 126 | |
| REIMB | REIMB_KELA(3005)_ICD10(M058) | Tofacitinib, Other seropositive rheumatoid arthritis | 80 | |
| REIMB | REIMB_KELA(293)_ICD10(M05) | Baricitinib, Seropositive rheumatoid arthritis | 74 | |
| REIMB | REIMB_KELA(291)_ICD10(M05) | Tofacitinib, Seropositive rheumatoid arthritis | 73 | |
| REIMB | REIMB_KELA(3006)_ICD10(M05) | Baricitinib, Seropositive rheumatoid arthritis | 70 | |
| REIMB | REIMB_KELA(313)_ICD10(M059) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Seropositive rheumatoid arthritis, unspecified | 59 | |
| REIMB | REIMB_KELA(3005)_ICD10(M05) | Tofacitinib, Seropositive rheumatoid arthritis | 54 | |
| REIMB | REIMB_KELA(281)_ICD10(M059) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Seropositive rheumatoid arthritis, unspecified | 51 | |
| REIMB | REIMB_KELA(3029)_ICD10(M05) | Upadacitinib, Seropositive rheumatoid arthritis | 26 | |
| REIMB | REIMB_KELA(298)_ICD10(M05) | Name not found, Seropositive rheumatoid arthritis | 25 | |
| REIMB | REIMB_KELA(298)_ICD10(M058) | Name not found, Other seropositive rheumatoid arthritis | 25 | |
| REIMB | REIMB_KELA(3029)_ICD10(M058) | Upadacitinib, Other seropositive rheumatoid arthritis | 24 | |
| REIMB | REIMB_KELA(202)_ICD9(M05) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found | 11 | |
| REIMB | REIMB_KELA(313)_ICD10(M050) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Felty's syndrome | 8 | |
| REIMB | REIMB_KELA(202)_ICD10(M056) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found | 6 | |
| REIMB | REIMB_KELA(281)_ICD10(M050) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Felty's syndrome | 6 | |
| REIMB | REIMB_KELA(3048)_ICD10(M058) | Name not found, Other seropositive rheumatoid arthritis | 5 |